Everolimus-induced hematologic changes in patients with metastatic breast cancer

Medicine and Dentistry

• Adverse Event 20%
• Anemia 40%
• Blood 20%
• Breast Cancer 20%
• Cells 20%
• Clinical Trial 20%
• Drug 20%
• Erythrocyte 20%
• Everolimus 100%
• Hemoglobin Determination 20%
• Hemoglobins 20%
• Immunosuppressive Treatment 20%
• Infection 20%
• Leukocyte 20%
• Leukopenia 40%
• Lymphocyte 20%
• Lymphocytopenia 20%
• Mean Corpuscular Volume 40%
• Mechanistic Target of Rapamycin 20%
• Metastatic Breast Cancer 100%
• Microcytosis 20%
• Mixed Model 20%
• Neutrophil 20%
• Nonoxinol 9 20%
• Oncologist 20%
• Patient 100%
• Student T Test 20%
• Therapeutic Procedure 40%
• Thrombocytopenia 40%
• Toxicity 40%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 25%
• Anemia 50%
• Breast Cancer 25%
• Clinical Trial 25%
• Drug 25%
• Everolimus 100%
• Hemoglobins 100%
• Infection 25%
• Leukopenia 50%
• Lymphocytopenia 25%
• Mammalian Target of Rapamycin 25%
• Metastatic Breast Cancer 100%
• Microcytosis 25%
• Mixed Model 25%
• Nonoxynol-9 25%
• Thrombocytopenia 50%
• Toxicity 50%

Immunology and Microbiology

• Blood Cell Count 25%
• Breast 100%
• Cells 25%
• Dose 25%
• Everolimus 100%
• Hemocyte 25%
• Immunity 25%
• Leukocyte Count 25%
• Lymphocyte 25%
• Lymphocytopenia 25%
• Mean Corpuscular Hemoglobin 75%
• Mean Corpuscular Volume 50%
• Neutrophil Granulocyte 25%
• Nonoxynol-9 25%
• Sirolimus 25%
• Time 75%